<li>amphotericin b deoxycholate<p>amphotericin b deoxycholate and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Contraindicated.</p></li><li>atorvastatin<p>cyclosporine increases toxicity of atorvastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>bosentan<p>cyclosporine will increase the level or effect of bosentan by  Other (see comment). Contraindicated. may increase plasma concentrations of OATP substrates</p></li><li>cidofovir<p>cidofovir and cyclosporine both increase  nephrotoxicity and/or ototoxicity. Contraindicated.</p></li><li>elbasvir/grazoprevir<p>cyclosporine increases levels of elbasvir/grazoprevir by Other (see comment). Contraindicated. 
Comment: Coadministration with strong OATP1B1/3 inhibitors may increase the risk of ALT elevations owing to a significant increase in grazoprevir plasma concentrations.</p></li><li>flibanserin<p>cyclosporine will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of flibanserin with moderate or strong CYP3A4 inhibitors is contraindicated. Severe hypotension or syncope can occur.</p></li><li>lomitapide<p>cyclosporine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increases lomitapide levels several folds.</p></li><li>mifepristone<p>mifepristone increases levels of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated with CYP3A substrates that have a narrow therapeutic index .</p></li><li>neomycin po<p>cyclosporine and neomycin po both increase  nephrotoxicity and/or ototoxicity. Contraindicated.</p></li><li>pitavastatin<p>cyclosporine increases toxicity of pitavastatin by Other (see comment). Contraindicated. 
Comment: OATP1B1 inhibitors may increase risk of myopathy.</p></li><li>saquinavir<p>cyclosporine will increase the level or effect of saquinavir by  Other (see comment). Contraindicated. may increase plasma concentrations of OATP substrates</p></li><li>simvastatin<p>cyclosporine will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Contraindicated.  Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure.<span><br><br></span>cyclosporine will increase the level or effect of simvastatin by  Other (see comment). Contraindicated. OATP1B1 inhibitors may increase risk of myopathy</p></li><li>sitaxentan<p>cyclosporine increases levels of sitaxentan by unknown mechanism. Contraindicated. Possibly due to OATP transporter protein inhibition.</p></li>